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Abstract: Cancers can cause some proteins to be aberrantly excreted or released in the 
urine, which can be used as biomarkers. To screen for potential biomarkers for endometrial 
cancer (ECa), the urinary proteins from patients who were newly diagnosed with early 
stage ECa and untreated controls were separated using two-dimensional gel electrophoresis 
(2-DE) and followed by image analysis. The altered levels of zinc alpha-2 glycoprotein, 
alpha 1-acid glycoprotein, and CD59 were detected in the patients compared to the 
controls. In addition, the urine of the ECa patients was also found to contain relatively 
lower levels of a fragment of nebulin when the 2-DE separated urinary proteins were probed 
using champedak galactose binding (CGB) lectin. The different levels of the nebulin 
fragment were further validated by subjecting the urinary protein samples to CGB lectin 
affinity chromatography and analysis of the bound fractions by LC-MS/MS. Our data is 
suggestive of the potential use of the differentially expressed urinary proteins as 
biomarkers for ECa although this requires further extensive validation on clinically 
representative populations.  
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1. Introduction 
Endometrial cancer (ECa) is one of the most common gynecological malignancies. It constitutes 6% 
of total cancers affecting women worldwide [1]. The diagnosis of ECa is very dependent on 
endometrial biopsy, which is invasive and highly subjective. As such, ECa is difficult to diagnose, 
particularly at the early stage of the malignancy. Up until now, no tumor marker has been established 
specifically for ECa, even though several serum markers that are known to be non-specific are 
currently being applied for its diagnosis [2]. Identification of proteins that are differentially expressed 
in the urine of ECa patients at an early stage may facilitate the development of a method to efficiently 
diagnose ECa non-invasively. These markers not only assist in the early and accurate identification of 
ECa patients, which is important for the patients’ survival, but also make the invasive biopsy 
procedure unnecessary for non-ECa patients.  
Urine has become one of the attractive biofluids to screen for potential protein biomarkers. It 
promises a convenient method of disease detection and monitoring because it can be easily and 
noninvasively obtained from the patients. Urinary protein biomarkers have been reported to be used for 
the detection of cancers of the kidney, bladder and prostate [3]. One of the more recent and popular 
methods used to screen for the possible presence of potential biomarkers in the urine involves the 
proteomics technology [4,5]. When subjected to two-dimensional gel electrophoresis (2-DE), urinary 
proteins may be profiled on the basis of the differences in isoelectric point and molecular weight. 
These proteins may also be quantified by densitometry and identified using mass spectrometry and 
database searches. Since urine usually harbors hydrophilic molecules in the form of glycoproteins, 
lectins may be additionally employed in the proteomics method to specifically target the presence of 
proteins with specific oligosaccharide structures. 
In the present study, the urine of patients who were newly diagnosed with ECa and control subjects 
was analyzed using 2-DE, densitometry and tandem mass spectrometry to screen for proteins that are 
differentially expressed. Aside from the conventional gel-based proteomics approach, a lectin that 
binds to the O-glycans of glycoproteins was also used to specifically profile the O-glycoproteins in the 
urine of the ECa patients and control subjects. Many O-glycoproteins had previously been implicated 
with cancer [6–9]. Hence, this lectin was chosen because it specifically binds to the oligosaccharide 
moieties of O-glycoproteins [10,11]. 
2. Results  
2.1. Profiling of Urinary Proteins by 2-DE 
Comparable 2-DE urine protein profiles of patients with ECa and control subjects were obtained 
when their urinary protein samples were subjected to 2-DE followed by silver staining. Figure 1 shows 
representative urine proteome maps of the controls (panel A) and ECa patients (panel B). Seven 
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protein clusters appeared to be consistently resolved in all the 2-DE maps of the patients and controls. 
When subjected to the MALDI-ToF MS/MS analysis, the protein clusters were identified as 
kininogen 1 (KNG), alpha-1 acid glycoprotein (AAG), zinc alpha-2 glycoprotein (ZAG), CD59, 
protein AMBP (AMBP), Ig gamma 3 chain C region (IgG3C) and Ig kappa chain C region (IgKC). 
Table 1 shows the mass spectrometric identification data of the urinary proteins that were resolved  
by 2-DE.  
Figure 1. Typical two-dimensional gel electrophoresis (2-DE) urinary protein profiles. The 
labeled spot clusters are proteins which consistently appeared in profiles of control 
subjects. Panels (A) and (B) refer to the profiles of a control subject and a patient with 
stage IB endometrial cancer (ECa), respectively.  
 














KNG Kininogen P01042 71/6.34 68 7 
IGHG3 Ig γ3 chain C region P01860 41/8.46 16 3 
AAG α1-acid glycoprotein P19652 23/5.03 241 16 
ZAG Zinc α2 glycoprotein P25311 33/5.57 134 20 
AMBP Protein AMBP P02760 39/5.95 50 12 
IGKC Ig λ1 chain C region P01834 11/5.58 141 32 
CD59 CD59 glycoprotein P13987 14/6.02 121 18 
+ Protein entry names are from the UniProtKB database [12]. # Accession numbers are from the Mascot 
search engine [13]. 
2.2. Image Analysis of 2-DE Separated Urinary Proteins 
When image analysis was performed using the Image Master 2D Platinum Software version 7.0, it 
was apparent that the levels of the proteins detected in the urine of ECa patients were comparable to 
those of the controls, except for AAG, ZAG and CD59. The intensities of AAG and ZAG were more 
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than 10-fold higher in the patients’ proteome map, whilst the CD59 protein cluster was barely detected 
in the 2-DE profiles of the patients’ urine samples. Table 2 demonstrates the average percentage of 
volume contribution of the seven detected urinary proteins.  
Table 2. Mean percentage of volume contribution of urinary proteins.  
Urinary Proteins Mean % Vol ± SEM p Fold Changes * Control (n = 11) ECa (n = 7) 
AAG 0.161 ± 0.072 2.746 ± 0.717 0.001 +17.1 
ZAG 0.175 ± 0.045 2.184 ± 0.592 0.001 +12.5 
CD59 2.575 ± 0.497 0.177 ± 0.070 0.002 −14.6 
KNG 5.137 ± 1.826 0.945 ± 0.491 0.108 ns 
IGKC 14.785 ± 2.197 18.840 ± 2.651 0.286 ns 
AMBP 8.941 ± 1.706 12.837 ± 3.430 0.306 ns 
IGHG3 4.014 ± 1.221 4.554 ± 1.706 0.807 ns 
* Fold expression changes are relative to the control values; (+) increase in expression; (–) decrease 
in expression; ns – not statistically significant; A p-value of less than 0.0214 was considered significant.  
2.3. Profiling of Urinary O-Glycoproteins 
To exclusively target the O-glycoproteins in the urine samples, 2-DE separated urinary proteins 
were transferred onto a nitrocellulose membrane and probed with enzyme-conjugated CGB lectin. The 
2-DE membrane profiles that were developed using the CGB lectin were entirely different from those 
generated by silver staining (Figure 2). Six clusters of O-glycoproteins were consistently detected in 
the urinary membrane profiles. In addition, one O-glycoprotein spot, with a molecular mass of 
approximately 51 kDa, seemed to appear in the profiles of all the control samples that were analyzed 
but faintly appeared in only one of the urine samples from patients with ECa. When the membrane 
profiles were subjected to image analysis, the levels of all urinary O-glycoproteins appeared comparable 
between the ECa patients and the controls except for the 51 kDa protein spot, which was 10.6-fold 
higher in the controls compared to the ECa patients (Table 3, panel A). To identify the sole aberrantly 
expressed urinary O-glycoprotein, the spot was excised and subjected to on-membrane trypsin 
digestion and analyzed by mass-spectrometry. Panel B of Table 3 demonstrates the MS/MS data obtained, 
which identified the O-glycoprotein spot as that of nebulin, when a database search was performed.  
Table 3. Relative expression (A) and identification of nebulin (B).  
(A) Mean % Vol ± SEM p Fold Changes 
Control (n = 11) ECa (n = 7) 
1.08 ± 0.172 0.102 ± 0.095 0.001 −10.6 






P20929 775/9.11 64 1 * 
* relative to native nebulin molecule. 
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Figure 2. Typical 2-DE urinary O-glycoprotein profiles. Panels (A) and (B) refer to 2-DE 
urinary O-glycoprotein profiles of a control subject and a patient with stage IB ECa, 
respectively. Spot clusters that are marked in boxes are proteins, which were consistently 
detected by CGB lectin. NEB refers to nebulin. The acidic side of the membranes is to the 
left and the relative molecular mass declines from the top.  
 
2.4. Immobilized CGB Lectin Affinity Chromatography and LC-MS/MS  
To validate the data that was obtained from the Western blot-lectin analysis, pooled urinary protein 
samples from the ECa patients as well as those of the controls were independently subjected to CGB 
lectin affinity chromatography and their bound fractions were then analyzed using LC-MS/MS. Based 
on a minimum of 90% protein probability confidence, more than 200 peptides were considered 
identified, which included that of nebulin. Table 4 lists the O-glycosylated proteins that were isolated 
using the CGB lectin or those potentially known to be O-glycosylated. The nebulin peptide spectrum 
with the de novo sequence K.AYELQSDNVYKADLEWLRGIGWMPNDSVSVNHA.K (amino acid 
positions 4103–4136) apparently appeared only in the profile that was generated from the pooled 
control urine samples but not in that which was obtained from the pooled urine of ECa patients. 







Protein AMBP P02760 Secreted O-linked 
ATP synthase subunit beta, mitochondrial P24539 Membrane Potential O-linked 
Serotransferrin P02787 Secreted O-linked  
Transmembrane protein 110 Q86TLZ Membrane Potential O-linked 
Phosphoinositide-3 kinase interacting protein 1 Q96FE7 Membrane O-linked 
Ribonuclease pancreatic P07998 Secreted Potential O-linked 
Prostaglandin-H2-D isomerase P41222 Secreted Potential O-linked 
Membrane bound transcription factor site-1 protease Q14703 Membrane Potential O-linked 
Homeobox protein engrailed 2 P19622 Nucleus Potential O-linked 
Actin, cytoplasmic 1 P60709 Cytoplasmic Potential O-linked 
Neurofilament medium polypeptide P07197 Cytoplasmic O-linked 
CD55 decay-accelerating factor splicing variant 4 Q14UF3 Membrane Potential O-linked 
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Table 4. Cont.  




Leucine rich alpha 2 glycoprotein P02750 Secreted O-linked 
Spondin-2 Q9BUD6 Secreted Potential O-linked 
Protein RRP5 homolog Q14690 Nucleus Potential O-linked 
CD44 antigen P16070 Membrane O-linked 
Phosphatidylinositol-3,4,5-triphosphate 5-
phosphatase-1 
Q92835 Membrane Potential O-linked 
Solute carrier family 12 member 6 Q9UHW9 Membrane Potential O-linked 
Mucin-5B Q9HC84 Secreted O-linked 
Major facilitator superfamily domain containing 
protein 10 
Q14728 Membrane Potential O-linked 
PDZ and LIM domain protein 5 Q96HC4 Membrane Potential O-linked 
Leukocyte associated immunoglobulin-like receptor 1 Q6GTX8 Membrane Potential O-linked 
Tumor necrosis receptor superfamily member 16 P08138 Membrane Potential O-linked 
Lipocalin-1 P31025 Secreted Potential O-linked 
Amyloid beta A4 P05067 Membrane O-linked 
Nebulin P20929 Cytoplasmic Potential O-linked 
Transcription factor HES-2 Q9Y543 Nucleus Potential O-linked 
Rho GTPase-activating protein 12 P20936 Cytoplasmic Potential O-linked 
Solute carrier family 13 member 3 Q8WWT9 Membrane Potential O-linked 
Sodium/bile acid contransporter Q14973 Membrane Potential O-linked 
Bromodomain-containing protein 3 Q15059 Nucleus Potential O-linked 
Inter alpha trypsin inhibitor heavy chain H4 Q14624 Secreted O-linked 
Ig gamma-1 chain C region P01857 Secreted Potential O-linked 
Ig gamma-2 chain C region P01859 Secreted Potential O-linked 
Ig alpha-1 chain C region P01876 Unknown O-linked 
Ig lambda-1 chain C region  P0CG04 Unknown Potential O-linked 
# Types of glycan as annotated by UniProt; glycosylation potential was determined by NetOGlyc 3.1 [14]. 
3. Discussion 
In the present study, the different altered levels of ZAG, AAG and CD59 were initially detected in 
the urine samples of patients with ECa compared to the controls. While the levels of ZAG and AAG 
were significantly increased, the expression of CD59 was much lower in the ECa patients. These 
proteins have been previously identified as potential biomarkers for various different types of  
cancers (Table 5). 
ZAG generally functions as a stimulator of lipolysis although it is also known to have other 
functions such as being a carrier protein, an immunoregulator and a cell adhesion molecule [15]. At the 
same time, ZAG has also been associated with cancer, as the levels of the protein have been reported 
to be increased in the sera of patients with cancers of the prostate [16] and cervix [7]. This was 
postulated to be due to the changes in the levels of adipokines and estrogen in the patients. The 
increase in levels of ZAG in the urine of patients with ECa shown in this study may reflect the change 
that occurred in the serum.  
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Table 5. Identification of CD59, ZAG, AAG and NEB as potential biomarkers. Check this table.  
Protein Type of Cancer Sample Type Reference 







































NEB Pancreatic  
Gastric 




A comparable trend of changes in both the serum and urine samples was also observed in the case 
of AAG in patients with ECa. AAG was also found to be elevated in the urine of ECa patients in this 
study. And other researchers have previously reported its increased levels in the serum of patients 
suffering from several different cancers including ECa [26,29].  
The decrease in the levels of CD59 in the urine of patients with bladder cancer [4], pancreatic ductal 
adenocarcinoma [30] and ovarian cancer [5] has been previously reported. CD59, also known as 
protectin, is a cell surface molecule that functions to inhibit the membrane attack complex of the 
complement pathway. The data of our present study further demonstrates decreased levels of CD59 in 
the urine of patients with ECa. Our data is also compatible with the report on the altered expression of 
CD59 in malignant tissues obtained from patients with ECa [19].  
When similar 2-DE separated urinary proteins were transferred onto nitrocellulose membranes and 
probed with enzyme-conjugated CGB lectin, a different profile consisting of only O-glycosylated 
proteins was obtained. Comparative densitometry analysis of the 2-DE membrane profiles generated 
from patients and controls demonstrated the significant altered levels of a single O-glycoprotein, which 
was subsequently identified as a 51 kDa fragment of nebulin. The nebulin fragment spot may not be 
detected in the earlier 2-DE experiments probably because of its relatively low amount in the urine 
samples. The absence or low levels of the nebulin fragment in the urine of patients with ECa relative to 
the controls was further confirmed when urinary O-glycosylated protein fractions obtained from 
passing pooled urine samples to CGB lectin affinity chromatography were analyzed using LC-MS/MS. 
Nebulin, a protein with a deduced molecular weight of 772.9 kDa functions as a template for 
polymerization of actin [31]. The protein is expressed predominantly in the thin filaments of striated 
muscle. It is known to be glycosylated, although the precise structure of its glycan moiety has never 
been characterized [32]. Hence, the result of the CGB lectin analyses performed in this study is a form 
of evidence that nebulin is O-glycosylated. The low molecular weight of the nebulin spot detected in 
the 2-DE experiments is indicative of a truncated or cleaved protein. The reduced levels of tissue 
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nebulin are commonly associated with myopathy [33]. However, its increased levels in the pancreatic 
juice are believed to be associated with the cellular turnover in patients with pancreatic cancer [27]. To 
the best of our knowledge, there is no previous report on the detection of nebulin or its fragment in the 
urine, but the protein has been detected in other biofluids such as serum [34] and pancreatic  
juice [27]. 
4. Experimental Section  
4.1. Urine Samples and Processing 
Urine samples were obtained from patients newly diagnosed with stages IB and IIA/B ECa (n = 7) 
in the morning at the Gynecological Clinic, University of Malaya Medical Centre (UMMC), Kuala 
Lumpur, prior to any treatment or surgery. All patients were confirmed with negative diagnosis for 
other diseases. Table 6 demonstrates the clinical data of patients involved in the study. Control urine 
samples (n = 11) were obtained randomly from age-matched healthy women. Samples were obtained 
with the patients’ consent and approval granted by the Ethical Committee of UMMC in accordance to 
the ICH GCP guideline and the declaration of Helsinki. The samples were immediately added with 
sodium azide to a final concentration of 20 mM to inhibit any bacterial growth. To remove cells and 
debris, the samples were centrifuged at 10,000 rpm at 4 °C. The supernatant was collected and 
dialyzed against four changes of 1 L unsterile distilled water at the same temperature in order to reduce 
the concentration of salt, which would affect the subsequent analyses. The urine samples were 
aliquoted, freeze-dried and kept at −80 °C for a period of not more than a month. The protein content 
was determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific, Rockford, USA). 

















1 IB No No Yes Yes No Normal 
2 IB No No Yes Yes No Normal 
3 IB No No No Yes No Normal 
4 IB No No No Yes No Normal 
5 IB No No No Yes No Normal 
6 IIA No Yes No Yes No Normal 
7 IIB No No No No No Normal 
4.2. Two-Dimensional Electrophoresis and Silver Staining  
2-DE was performed as previously reported [35,36]. Briefly, 300 µg of freeze dried urine samples 
were solubilized and subjected to isoelectric focusing in 11 cm rehydrated precast Immobiline 
Drystrips pH 3–10 overnight, followed by first dimension separation with IPGphor 3 (GE Healthcare 
Biosciences, Uppsala, Sweden). For the second dimension separation, the focused samples in the strips 
were subjected to electrophoresis using 12.5% polyacrylamide gel in the presence of SDS. Silver 
staining of the 2-DE gels was performed based on the method described by Heukeshorven and  
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Dernick [37]. For mass spectrometry analysis, a modified silver staining method by Shevchenko et al., 
was used [38].  
4.3. Image Analysis 
The silver stained 2-DE gels (as well as lectin-developed membranes in section 4.6) were scanned 
using ImageScanner III (GE Healthcare Bioscience, Uppsala, Sweden). Image analysis was restricted 
to protein spot clusters that appeared consistently within each group of urine samples. The levels of 
proteins in each sample were calculated as a percentage of volume contribution (% vol) in which the 
volume of contribution refers to the volume percentage of a protein taken against the total spot volume 
of all the proteins, in order to eliminate the possible variations due to staining. All values are presented 
as mean ± S.E.M (standard error of the mean). The Student’s t-test was used to analyze the 
significance of difference between controls and ECa patients. A value of p < 0.05 was initially 
accepted as significantly different. The false discovery rate control was then performed using the 
method of Benjamini and Hochberg [39]. The p value was then corrected, with those <0.0214 
considered to be significantly different. 
4.4. On-Membrane Digestion 
On-membrane digestion was performed according to the method described by Luque-Garcia  
et al. [40], with modifications. Briefly, the nitrocellulose membrane was blocked with 1% PVP-40 
(w/v) in TBS, washed three times with the same buffer and incubated with the HRP-conjugated CGB 
lectin. After the development of the membrane as previously described, the protein spot was excised 
and destained with 0.1% EDTA dihydrate for 30 minutes. Horseradish peroxidase-conjugated  
CGB lectin was stripped by washing the spot with 0.5 and 1.0 M melibiose in Tris-HCl pH 7.5 for  
30 minutes each. Then, the stripped spot was blocked with 0.5% (w/v) PVP-40 in 100 mM acetic acid 
at 37 °C for 30 minutes and digested with 12.5 ng/µL trypsin in 50 mM NH4HCO3 buffer overnight. 
After digestion, the sample was dissolved in acetone, vortexed and incubated for 30 minutes. The 
peptide was dissolved in 10 mg/mL of CHCA in 1% TFA of 50:50 ACN and MilliQ water after the 
removal of acetone, which contained a nitrocellulose membrane.  
4.5. MALDI-ToF Mass Spectrometry 
Plugs of proteins of interest from the 2-DE gels were subjected to in-gel digestion as previously 
described [41]. Identification of a protein by MALDI mass spectrometry was performed on one of the 
representative gels, using the Applied Biosystem 4800 Proteomics Analyzer. The mass standard kit 
(Applied Biosystems/MDS Sciex, Toronto, Canada) was used as the calibrator for the MS/MS analysis. 
The data from the MS/MS was submitted to the MASCOT search engine for protein identification. 
4.6. Western Blotting and Detection by CGB Lectin 
CGB lectin was purified from the crude extracts of the champedak seeds using immobilized 
galactose affinity chromatography. The purity of the lectin was confirmed using SDS-PAGE 18% 
polyacrylamide gel. Western blotting was performed by electrophoretically transferring 2-DE-separated 
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urinary proteins from gels onto nitrocellulose membrane (0.45 µm) using the NovaBlot Kit of 
Multiphor II Electrophoresis system (GE Healthcare Bioscience, Uppsala, Sweden) at 0.8 mA/cm2 for 
1 hour. The membrane was blocked with 3% w/v gelatin in Tris-buffered saline Tween-20 (TBST), 
pH7.5 for 1 hour at room temperature and washed three times with the same buffer. Detection of 
transferred urinary O-glycoproteins was performed using horseradish peroxidase-conjugated CGB 
lectin. Blots were developed using metal enhanced DAB substrate kit for horseradish peroxidase 
(Pierce, Rockford, USA).  
4.7. CGB Lectin Affinity Separation and LC-MS/MS 
CGB lectin was conjugated to CNBr-activated Sepharose 4B (GE Healthcare Bioscience, Uppsala, 
Sweden), based on the manufacturer’s instructions. Column was equilibrated with PBS, pH 7.2,  
prior to the application of pooled urinary proteins (400 µg). Eluted fractions were monitored by 
measurement of absorbance at 280 nm. Elution of urinary O-glycoproteins was performed using 0.5 M 
of D-melibiose in PBS. Bound fractions collected from both columns were pooled, dialyzed and 
concentrated with the vivaspin column concentrator (Sartorius Stedim Biotech, Goettingen, Germany) 
and send to The Vincent Coates Foundation Mass Spectrometry Laboratory, Stanford University Mass 
Spectrometry for LC-MS/MS analysis.  
5. Conclusions  
In summary, the data of this study is suggestive of the potential use of urinary ZAG,  
AAG, CD59 and a 51 kDa fragment of nebulin as complementary biomarkers for ECa. However, this 
requires further extensive validation in a study that has to be carried out on clinically representative 
populations. Such a study cannot be possibly performed using the present gel- and lectin-based 
proteomics analyses. Nevertheless, with the identification of the potential urinary biomarkers in the 
present study, validation is easily carried out in a large-scale investigation using assays like the ELISA.  
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